Parkin reverses intracellular β‐amyloid accumulation and its negative effects on proteasome function
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The significance of intracellular β‐amyloid (Aβ 42) accumulation is increasingly recognized in Alzheimer's disease (AD) pathogenesis. Aβ removal mechanisms that have attracted attention include IDE/neprilysin degradation and antibody‐mediated uptake by immune cells. However, the role of the ubiquitin‐proteasome system (UPS) in the disposal of cellular Aβ has not been fully explored. The E3 ubiquitin ligase Parkin targets several proteins for UPS degradation, and Parkin mutations are the major cause of autosomal recessive Parkinson's disease. We tested whether Parkin has cross‐function to target misfolded proteins in AD for proteasome‐dependent clearance in SH‐SY5Y and primary neuronal cells. Wild‐type Parkin greatly decreased steady‐state levels of intracellular Aβ 42, an action abrogated by proteasome inhibitors. Intracellular Aβ 42 accumulation decreased cell viability and proteasome activity. Accordingly, Parkin reversed both effects. Changes in mitochondrial ATP production from Aβ or Parkin did not account for their effects on the proteasome. Parkin knock‐down led to accumulation of Aβ. In AD brain, Parkin was found to interact with Aβ and its levels were reduced. Thus, Parkin is cytoprotective, partially by increasing the removal of cellular Aβ through a proteasome‐dependent pathway. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 7×
“1 (Shimura et al., 2000) were amplified along with the cytomegalovirus (CMV) promoter [forward primer GAT CAT”
BackgroundMethodInfluentialShimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., & Selkoe, D. J. (2001) · Science · doi:10.1126/science.1060627 · Cited by 1,053
Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice
Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401135200 · Cited by 995
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 2×
“There is also evidence to suggest that extracellular, parenchymal Ab plaques in the brain are derived from degenerating Ab42-laden neuronal cell bodies (Gouras et al., 2000; D’Andrea et al., 2001).”
BackgroundImpaired Proteasome Function in Alzheimer's Disease
Keller, J. N., Hanni, K. B., & Markesbery, W. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750436.x · Cited by 848 · cited 2×
“For instance, damage to proteasome activities is readily detected in AD brain (Keller et al., 2000b; Lopez Salon et al., 2000), wherein ubiquitin (Ub) and its conjugates are deposited in neuritic plaque and PHF/NFT structures (Perry et al., 1987; Morishima-Kawashima et al., 1993).”
BackgroundInsulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Chung, K. K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2001) · Nature Medicine · doi:10.1038/nm1001-1144 · Cited by 750 · cited 2×
“In cell culture systems, Parkin fusion proteins have been shown to interact with several proteins, including the a-synuclein-binding protein synphilin-1 (Chung et al., 2001), actin filaments (Huynh et al.”
BackgroundPerry, G., Friedman, R., Shaw, G., & Chau, V (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3033 · Cited by 623 · cited 2×
“For instance, damage to proteasome activities is readily detected in AD brain (Keller et al., 2000b; Lopez Salon et al., 2000), wherein ubiquitin (Ub) and its conjugates are deposited in neuritic plaque and PHF/NFT structures (Perry et al., 1987; Morishima-Kawashima et al., 1993).”
BackgroundAltered proteasomal function in sporadic Parkinson’s disease
St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8050 · Cited by 573 · cited 1×
“For Parkinson’s disease, a large body of evidence exists to support proteasome dysfunction as a major contributor to disease pathogenesis (McNaught et al., 2003; Petrucelli and Dawson, 2004; Ross and Pickart, 2004; Snyder and Wolozin, 2004).”
BackgroundZhang, Y., McLaughlin, R., Goodyer, C., & LeBlanc, A. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200110119 · Cited by 418
Cited by
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 596
Salminen, A., Kaarniranta, K., Kauppinen, A., Ojala, J., Haapasalo, A., Soininen, H., & Hiltunen, M. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.002 · Cited by 364
Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases
Zheng, Q., Huang, T., Zhang, L., Zhou, Y., Luo, H., Xu, H., & Wang, X. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00303 · Cited by 311
SQSTM1/p62: a potential target for neurodegenerative disease
Ma, S., Attarwala, I. Y., & Xie, X.-Q. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00516 · Cited by 185
The Ubiquitin-Proteasome System in Neurodegeneration
McKinnon, C., & Tabrizi, S. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5802 · Cited by 165
“The potential therapeutic benefit of parkin over-expression may not be restricted to PD, as parkin has also been shown to interact with A b and was found to be depleted in postmortem AD brains (156).”
Emerging role of p62/sequestosome-1 in the pathogenesis of Alzheimer's disease
Salminen, A., Kaarniranta, K., Haapasalo, A., Hiltunen, M., Soininen, H., & Alafuzoff, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.005 · Cited by 153
Lonskaya, I., Hebron, M. L., Desforges, N. M., Schachter, J. B., & Moussa, C. E.-H. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1112-3 · Cited by 152
“WT and not mutant loss-of-function parkin increases proteasome activity [25, 30, 31], leading to degradation of ubiquitinated proteins, while amyloid stress alters parkin solubility [13].”
BackgroundSelf-citationLee, H.-K., Kwon, B., Lemere, C. A., de la Monte, S., Itamura, K., Ha, A. Y., & Querfurth, H. W. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161029 · Cited by 57
“Nevertheless, in previous work, we showed that viral vector-based A (cid:2) expression had the same subcellular fractionation into microsomes and mitochondria [108] and co-localization within endoplasmic reticulum and multivesicular bodies as reported in the transgenic 2576 mouse (APPswed) [62].”
Self-citationMinding the body: Psychotherapy and cancer survival
Spiegel, D. (2014) · British Journal of Health Psychology · doi:10.1111/bjhp.12061 · Cited by 53
Moussa, C. E.-H. (2015) · Neurodegenerative Diseases · doi:10.1159/000430888 · Cited by 13
Self-citation
Metadata
- Authors
- Rosen, K. M., Moussa, C. E. ‐., Lee, H., Kumar, P., Kitada, T., Qin, G., Fu, Q., & Querfurth, H. W.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2009-07-16
- Volume
- 88
- Issue
- 1
- Pages
- 167-178
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2022287604
- Cited by
- 95
- References
- 15
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.